Cargando…

Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [(18)F]AGAL Targeting Alpha-Galactosidase A Enzyme for Fabry Disease

Success of gene therapy relies on the durable expression and activity of transgene in target tissues. In vivo molecular imaging approaches using positron emission tomography (PET) can non-invasively measure magnitude, location, and durability of transgene expression via direct transgene or indirect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lohith, Talakad G., Kaittanis, Charalambos, Belanger, Anthony P., Ahn, Shin Hye, Sandoval, Phil, Cohen, Lawrence, Rajarshi, Girija, Ruangsiriluk, Wanida, Islam, Rizwana, Winkelmann, Christopher T., McQuade, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609273/ https://www.ncbi.nlm.nih.gov/pubmed/37894622 http://dx.doi.org/10.3390/molecules28207144

Ejemplares similares

Involvement of α-galactosidase OmAGAL2 in planteose hydrolysis during seed germination of Orobanche minor
por: Okazawa, Atsushi, et al.
Publicado: (2021)

Comparison of efficacy between subcutaneous and intravenous application of moss‐aGal in the mouse model of Fabry disease
por: Dabrowska‐Schlepp, Paulina, et al.
Publicado: (2023)

Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2023)

Optimizing human α-galactosidase for treatment of Fabry disease
por: Hallows, William C., et al.
Publicado: (2023)

Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease)
por: Hůlková, Helena, et al.
Publicado: (2010)

Influence of Co-Sputtered Ag:Al Ultra-Thin Layers in Transparent V(2)O(5)/Ag:Al/AZO Hole-Selective Electrodes for Silicon Solar Cells
por: Tom, Thomas, et al.
Publicado: (2020)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
por: Prabakaran, Thaneas, et al.
Publicado: (2011)

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease
por: Li, Ping, et al.
Publicado: (2019)

Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
por: Miller, James J., et al.
Publicado: (2019)

Nanoporous foam fabricated by dealloying AgAl thin film through supercritical fluid corrosion
por: Liu, Y. C., et al.
Publicado: (2018)

Electronic, Optical, and Vibrational Properties of an AgAlS(2) Crystal in a High-Pressure Phase
por: Rudysh, Myron Ya., et al.
Publicado: (2023)

Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations
por: Kim, Dae Hun, et al.
Publicado: (2013)

Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
por: Hofmann, Lukas, et al.
Publicado: (2017)

Automated radiosynthesis of [(11)C]UCB‐J for imaging synaptic density by positron emission tomography
por: Milicevic Sephton, Selena, et al.
Publicado: (2020)

Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy
por: Varlow, Cassis, et al.
Publicado: (2022)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease
por: Modrego, Andrea, et al.
Publicado: (2021)

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
por: Rodríguez-Castejón, Julen, et al.
Publicado: (2021)

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease
por: Monticelli, Maria, et al.
Publicado: (2023)

Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease
por: Wu, Yuan, et al.
Publicado: (2018)

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
por: Besada, Pedro, et al.
Publicado: (2021)

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones
por: Monticelli, Maria, et al.
Publicado: (2022)

Optimized and Automated Radiosynthesis of [(18)F]DHMT for Translational Imaging of Reactive Oxygen Species with Positron Emission Tomography
por: Zhang, Wenjie, et al.
Publicado: (2016)

Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds
por: Shegani, Antonio, et al.
Publicado: (2022)

Radiosynthesis and Evaluation of [(11)C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography
por: Wilson, Alan A., et al.
Publicado: (2012)

Correction to “Radiosynthesis, Preclinical and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds”
por: Shegani, Antonio, et al.
Publicado: (2023)

Replacement of α-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients
por: Keslová-Veselíková, Jana, et al.
Publicado: (2008)

Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease
por: Lukas, Jan, et al.
Publicado: (2013)

Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing α-Galactosidase A
por: Biferi, Maria Grazia, et al.
Publicado: (2020)

α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes
por: Jehn, Ulrich, et al.
Publicado: (2021)

Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype
por: Elsaid, Hassan O.A., et al.
Publicado: (2022)

Novel α-galactosidase A gene mutation in a Chinese Fabry disease family: A case report
por: Fu, An-Yi, et al.
Publicado: (2022)

A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease
por: Wu, Xiaoyang, et al.
Publicado: (2011)

Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
por: Shen, Jin-Song, et al.
Publicado: (2015)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy
por: Nakano, Sachie, et al.
Publicado: (2015)

Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease
por: Citro, Valentina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0kkf0dci0sfpkt1kbadn13ajjd